Economic implications of influenza and influenza vaccine

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 425-440

  Walsh, Julia A ^a   Maher, Cyrus ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CHILD HEALTH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG COST; FRANCE; GERIATRICS; GERMANY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; MACROECONOMICS; PANDEMIC INFLUENZA; PREGNANT WOMAN; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEASONAL INFLUENZA; SOCIOECONOMICS; UNITED STATES; VACCINATION;

EID: 79960101560     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0279-2_19     Document Type: Review

References (44)

1. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA (2006) Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 12(10):1548-1558
2. Schmier J, Li S, King JC Jr, Nichol K, Mahadevia PJ (2008) Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff (Millwood) 27(2):w96-104
3. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, Bianchi C, Colombo GL, Principi N (2006) Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24(5):629-635
4. Allsup S, Gosney M, Haycox A, Regan M (2003) Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess 7(24):iii-x, 1-65. PMID: 14499051
5. Allsup S, Haycox A, Regan M, Gosney M (2004) Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 16;23 (5):639-645
6. Simmerman JM, Lertiendumrong J, Dowell SF, Uyeki T, Olsen SJ, Chittaganpitch M et al (2006) The cost of influenza in Thailand. Vaccine 24(20):4417-4426
7. Newall AT, Scuffham PA (2008) Influenza-related disease: the cost to the Australian healthcare system. Vaccine. Dec 9;26(52):6818-6823
8. Molinari N, Ortega-Sanchez I, Massonnier M, Thompson W, Wortley P, Weintraub E et al (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25:5086-5096
9. Szucs T (1999) The socio-economic burden of influenza. J Antimicrob Chemother 44:11-15
10. Congressional Budget Office (2006) A potential influenza pandemic: an update on possible macroeconomic effects and policy issues. Congressional Budget Office, Washington
11. Meltzer M, Cox N, Fukuda K (1999) The economic impacts of pandemic influenza in the united states: priorities for intervention. Emerg Infect Dis 5(5):659-671
12. Burns A, van der Mensbrugghe D, Timmer H (2008) Evaluating the economic consequences of avian influenza. The World Bank, Washington
13. McKibbin W, Sidorenko A (2006) Global macroeconomic consequences of pandemic influenza. Lowy Institute for International Policy, Sydney
14. Bloom E, deWit V, Carangal-San Jose MJ (2005) Potential Economic Impact of an Avian Flu Pandemic on Asia. Washington, DC: Asian Development Bank. Economics and Research Department. ERD Policy Brief Series #42
15. Sander B, Nizam A, Garrison LP (2009) Economic evaluation of influenza pandemic mitigation strategies in the united states using a stochastic microsimulation transmission model. Value Health 12(2):226-233
16. Weycker D, Edelsberg J, Halloran ME, Longini IMJ, Nizam A, Ciuryla V et al (2005) Population-wide benefits of routine vaccination of children against influenza. Vaccine 23 (10):1284-1293
17. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K (2005) An economic analysis of annual influenza vaccination of children. Vaccine 23(8):1004-1014
18. Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ (2007) Costeffectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 25(47):8010-8020
19. Marchetti M, Kuhnel UM, Colombo GL, Esposito S, Principi N (2007) Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 3 (1):14-22
20. Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC (2001) Cost-effectiveness of influenza vaccination in high-risk children in argentina. Vaccine 19(30):4204-4213
21. Navas E, Salleras L, Dominguez A, Ibanez D, Prat A, Sentis J et al (2007) Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 25(16):3233-3239
22. Salleras L, Navas E, Dominguez A, Ibanez D, Prat A, Garrido P et al (2009) Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices. Vaccine 27(25-26):3454-3458
23. Skowronski DM, Woolcott JC, Tweed SA, Brunham RC, Marra F (2006) Potential costeffectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine 24(19):4222-4232
24. Cai L, Uchiyama H, Yanagisawa S, Kamae I (2006) Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Kobe J Med Sci 52 (3-4):97-109
25. Hoshi SL, Kondo M, Honda Y, Okubo I (2007) Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan. Vaccine 25(35):6511-6521
26. Wang ST, Lee LT, Chen LS, Chen TH (2005) Economic evaluation of vaccination against influenza in the elderly: an experience from a population- based influenza vaccination program in Taiwan. Vaccine 23(16):1973-1980
27. Scuffham PA, West PA (2002) Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20(19-20):2562-2578
28. Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ (1999) Economic evaluation of influenza vaccination. Assessment for the Netherlands. Pharmacoeconomics 16 (Suppl 1):33-40
29. Gutierrez JP, Bertozzi SM (2005) Influenza vaccination in the elderly population in Mexico: economic considerations. Salud Pública Méx 47(3):234-239
30. Nichol KL, Goodman M(1999) The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics 16(Suppl 1):63-71
31. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ (2006) Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 31(1):72-79
32. Ohkusa Y (2005) Policy evaluation for the subsidy for influenza vaccination in elderly. Vaccine 23(17-18):2256-2260
33. Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P et al (2002) Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 20 (Suppl 5):B50-B54
34. Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ (2001) Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy 56(3):215-234
35. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED (2002) Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 137(4):225-231
36. Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E et al (2006) Vaccinating healthcare workers against influenza to protect the vulnerable - is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 24 (19):4212-4221
37. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ et al (2000) Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284(13):1655-1663
38. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K (2003) Systematic review and economic decision modeling for the prevention and treatment of influenza A and B. Health Technol Assess 7(35):iii-iv, xi-xiii, 1-170
39. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT (2002) Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 62(7):1013-1024
40. Rothberg MB, Rose DN (2005) Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 118(1):68-77
41. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR (2000) Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283(11):1460-1468
42. Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE (2005) Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115 (5):1220-1232
43. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI (2007) Costeffectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 119 (4):684-697
44. Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. N Engl J Med 359(8):821-832